We cloned a novel member of the ETS family of transcription factors called MEF, from a human megakaryocytic leukemia cell line. MEF is a strong transcriptional activator that is expressed in immature and mature hematopoietic cells. We have demonstrated that MEF is phosphorylated by the cyclin A/CDK2 complex and have preliminarily shown that sequential phosphorylation leads to its degradation by the ubiquitin proteasome degradation pathway. After generating murine cDNA and genomic MEF clones, we created MEF """"""""knock-out"""""""" mice which have defects in NK and NK T cell development and abnormalities in the hematopoietic stem cell compartment. MEF -7- NK cells cannot lyse tumor cells, probably because perforin, an MEF target gene, is not expressed. Based on the phenotype of these mice, and the cell cycle dependent regulation of MEF function, we propose to further characterize the biological effects of MEF on hematopoietic stem cells, NK and NK T cells by utilizing MEF-null mice for several bone marrow transplant models (and for target gene identification) and by overexpressing MEF in hematopoietic progenitor cells. We will define the mechanisms of MEF action by identifying and characterizing MEF target genes in hematopoietic cells and by further characterizing the cell cycle dependent regulation of MEF expression. The studies proposed will define the role of MEF in regulating gene expression involved in hematopoietic stem cell behavior and innate immunity. These studies will contribute greatly to advances in the fields of stem cell transplantation and immune regulation.

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Research Project (R01)
Project #
Application #
Study Section
Hematology Subcommittee 2 (HEM)
Program Officer
Bishop, Terry Rogers
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Sloan-Kettering Institute for Cancer Research
New York
United States
Zip Code
Asai, Takashi; Hatlen, Megan A; Lossos, Chen et al. (2016) Generation of a novel, multi-stage, progressive, and transplantable model of plasma cell neoplasms. Sci Rep 6:22760
Xu, Haiming; Menendez, Silvia; Schlegelberger, Brigitte et al. (2012) Loss of p53 accelerates the complications of myelodysplastic syndrome in a NUP98-HOXD13-driven mouse model. Blood 120:3089-97
Liu, Yan; Liu, Fan; Yu, Hao et al. (2012) Akt phosphorylates the transcriptional repressor bmi1 to block its effects on the tumor-suppressing ink4a-arf locus. Sci Signal 5:ra77
Asai, Takashi; Liu, Yan; Di Giandomenico, Silvana et al. (2012) Necdin, a p53 target gene, regulates the quiescence and response to genotoxic stress of hematopoietic stem/progenitor cells. Blood 120:1601-12
Bazzoli, Elena; Pulvirenti, Teodoro; Oberstadt, Moritz C et al. (2012) MEF promotes stemness in the pathogenesis of gliomas. Cell Stem Cell 11:836-44
Huang, Gang; Zhao, Xinghui; Wang, Lan et al. (2011) The ability of MLL to bind RUNX1 and methylate H3K4 at PU.1 regulatory regions is impaired by MDS/AML-associated RUNX1/AML1 mutations. Blood 118:6544-52
Asai, Takashi; Liu, Yan; Bae, Narae et al. (2011) The p53 tumor suppressor protein regulates hematopoietic stem cell fate. J Cell Physiol 226:2215-21
Sashida, Goro; Bae, Narae; Di Giandomenico, Silvana et al. (2011) The mef/elf4 transcription factor fine tunes the DNA damage response. Cancer Res 71:4857-65
Sashida, Goro; Bazzoli, Elena; Menendez, Silvia et al. (2010) The oncogenic role of the ETS transcription factors MEF and ERG. Cell Cycle 9:3457-9
Miyata, Yasuhiko; Liu, Yan; Jankovic, Vladimir et al. (2010) Cyclin C regulates human hematopoietic stem/progenitor cell quiescence. Stem Cells 28:308-17

Showing the most recent 10 out of 33 publications